JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Raises Price Target to $385
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has maintained a Market Outperform rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and raised the price target from $381 to $385.
July 16, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has maintained a Market Outperform rating on Madrigal Pharmaceuticals and raised the price target from $381 to $385.
The raised price target and maintained Market Outperform rating by JMP Securities are positive signals for investors, likely leading to a short-term increase in MDGL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100